PT UBC Medical Indonesia Tbk (IDX:LABS)
Indonesia · Delayed Price · Currency is IDR 157.00
-2.00 (-1.26%)
Oct 9, 2026, 4:02 PM WIB
IDX:LABS Ratios and Metrics
Market cap in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 620,150 | 541,150 | 529,300 | - | - | - | |
Market Cap Growth | 11.35% | 2.24% | - | - | - | - |
Enterprise Value | 637,040 | 543,513 | 545,030 | - | - | - |
Last Close Price | 159.00 | 137.00 | 134.00 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 58.75 | 40.07 | 179.29 | - | - | - |
PS Ratio | 3.02 | 2.72 | 3.59 | - | - | - |
PB Ratio | 4.01 | 3.55 | 3.82 | - | - | - |
P/TBV Ratio | 4.11 | 3.66 | 3.97 | - | - | - |
P/FCF Ratio | - | 62.33 | - | - | - | - |
P/OCF Ratio | 46.62 | 23.64 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.10 | 2.73 | 3.69 | - | - | - |
EV/EBITDA Ratio | 19.81 | 16.47 | 25.81 | - | - | - |
EV/EBIT Ratio | 31.18 | 26.69 | 60.88 | - | - | - |
EV/FCF Ratio | - | 62.61 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.15 | 0.18 | 0.26 | 0.84 | 0.41 | 2.82 |
Debt / EBITDA Ratio | 0.73 | 0.83 | 1.68 | 2.63 | 1.54 | 2.31 |
Debt / FCF Ratio | - | 3.17 | - | - | - | - |
Net Debt / Equity Ratio | 0.11 | -0.09 | -0.05 | 0.77 | 0.39 | 1.57 |
Net Debt / EBITDA Ratio | 0.53 | -0.41 | -0.31 | 2.45 | 1.54 | 1.32 |
Net Debt / FCF Ratio | -3.70 | -1.57 | 0.32 | -1.10 | -1.02 | -0.45 |
Asset Turnover | 0.96 | 0.92 | 0.81 | 1.02 | 0.92 | - |
Inventory Turnover | 1.54 | 1.58 | 1.38 | 1.77 | 1.70 | - |
Quick Ratio | 0.92 | 1.02 | 1.18 | 0.41 | 0.30 | 0.23 |
Current Ratio | 2.80 | 2.53 | 3.02 | 1.23 | 0.99 | 0.70 |
Return on Equity (ROE) | 7.07% | 9.28% | 3.14% | 4.52% | 10.00% | - |
Return on Assets (ROA) | 5.98% | 5.90% | 3.08% | 2.71% | 2.08% | - |
Return on Invested Capital (ROIC) | 8.98% | 11.59% | 4.56% | 2.68% | 4.73% | 1.55% |
Return on Capital Employed (ROCE) | 13.00% | 13.10% | 5.90% | 8.30% | 7.00% | 28.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.70% | 2.50% | 0.56% | - | - | - |
FCF Yield | -0.73% | 1.60% | -3.87% | - | - | - |
Buyback Yield / Dilution | - | - | -67.78% | - | - | - |